Background:
Multiple sclerosis is an autoimmune chronic inflammatory disease of the central nervous system
that can lead to some serious disabilities. Despite using various immunomodulatory and anti-inflammatory drugs that have
therapeutic effects, they cannot reduce its progression completely, and have some unwanted side effects too.
The immunomodulatory and anti-inflammatory effects of the β-D-Mannuronic acid [M2000] have been proven in several
surveys, and the present research was designed to determine its toxicity and therapeutic effects in MS patients.
Methods:
This study was performed on 15 MS patients who took 25 mg/kg/day the oral form of the β-D-Mannuronic acid
for six months, and 15 healthy people as a control group. Serum levels of Urea, Creatinine, GGT, Vitamin D3, Uric acid,
and Anti-Phospholipids were compared to evaluate the therapeutic and possible toxic effects of this drug after this period.
Results:
Non- toxic effects through the study of Urea, Creatinine, GGT, and non-significant changes in Uric acid and AntiPhospholipids levels, besides a significant rise in Vitamin, D3 levels in the M2000 treated cases were found.
Conclusions:
Our results suggested that β-D-Mannuronic acid is a safe drug and has no toxicity when administered orally
and also has some therapeutic effects in MS patients.